

University of Groningen

ASO Visual Abstract

Merola, E; Pascher, A; Rinke, A; Bartsch, D K; Zerbi, A; Nappo, G; Carnaghi, C; Ciola, M; McNamara, M G; Zandee, W

Published in:
Annals of Surgical Oncology

DOI:
[10.1245/s10434-022-12049-3](https://doi.org/10.1245/s10434-022-12049-3)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Merola, E., Pascher, A., Rinke, A., Bartsch, D. K., Zerbi, A., Nappo, G., Carnaghi, C., Ciola, M., McNamara, M. G., Zandee, W., Bertani, E., Marcucci, S., Modica, R., Grützmann, R., Fazio, N., de Herder, W., Valle, J. W., Gress, T. M., Delle Fave, G., ... Pavel, M. E. (2022). ASO Visual Abstract: Radical Resection in Enteropancreatic Neuroendocrine Tumors-Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. *Annals of Surgical Oncology*, 29, 5580–5581. <https://doi.org/10.1245/s10434-022-12049-3>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



ASO Visual Abstract: Radical Resection in Enteropancreatic Neuroendocrine Tumors—Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence

E. Merola, MD, PhD^{1,2}, A. Pascher, MD, PhD^{3,4}, A. Rinke, MD, PhD⁵, D. K. Bartsch, MD, PhD⁶, A. Zerbi, MD, PhD^{7,8}, G. Nappo, MD⁸, C. Carnaghi, MD⁹, M. Ciola, MD¹⁰, M. G. McNamara, MD, PhD¹¹, W. Zandee, MD, PhD^{12,13}, E. Bertani, MD, PhD¹⁴, S. Marcucci, MD¹⁵, R. Modica, MD¹⁶, R. Grützmann, MD, PhD¹⁷, N. Fazio, MD, PhD¹⁸, W. de Herder, MD, PhD¹², J. W. Valle, MD, PhD¹¹, T. M. Gress, MD, PhD⁵, G. Delle Fave, MD, PhD^{18,19}, G. de Pretis², A. Perren, MD²⁰, B. Wiedenmann, MD, PhD²¹, and M. E. Pavel, MD, PhD^{1,2}

¹Division of Endocrinology, Department of Medicine 1, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; ²Department of Gastroenterology, Santa Chiara Hospital, Trento, Italy; ³Department of Surgery, Charité Universitätsmedizin, Berlin, Germany; ⁴Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Münster, Münster, Germany; ⁵Department of Gastroenterology, University Hospital Gießen and Marburg, Marburg, Germany; ⁶Department of Visceral, Thoracic and Vascular Surgery, Philipps-University Marburg, Marburg, Germany; ⁷Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; ⁸IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; ⁹Oncology Unit, Bolzano Central Hospital, Bolzano, Italy; ¹⁰Department of Surgery, Bolzano Central Hospital, Bolzano, Italy; ¹¹Division of Cancer Sciences, University of Manchester/Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, UK; ¹²Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, Rotterdam, The Netherlands; ¹³Division of Endocrinology, Department of Internal Medicine, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; ¹⁴Division of Gastrointestinal Surgery, European Institute of Oncology IRCCS, Milan, Italy; ¹⁵Department of Surgery 2, Santa Chiara Hospital, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy; ¹⁶Endocrinology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy; ¹⁷Department of Surgery, University Medical Center Erlangen, Erlangen, Germany; ¹⁸Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology IEO, IRCCS, Milan, Italy; ¹⁹Department of Gastroenterology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy; ²⁰Institute of Pathology, University of Bern, Bern, Switzerland; ²¹Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charité Universitätsmedizin, Berlin, Germany

In this multicenter series of 441 sporadic enteropancreatic neuroendocrine tumors (EP-NETs), 30% of patients recurred within 5 years after radical surgery (<https://doi.org/10.1245/s10434-022-11837-1>).

A nomogram for recurrence risk included disease stage, lymph node ratio, margin status, and grading to select potential candidates for adjuvant treatments.

E. Merola and A. Pascher share first authorship.

© Society of Surgical Oncology 2022

First Received: 22 April 2022

Accepted: 9 June 2022

Published Online: 4 July 2022

E. Merola, MD, PhD
e-mail: elettra.merola@apss.tn.it

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1245/s10434-022-12049-3>.

DISCLOSURE W. de Herder: advisory boards Ipsen and AAA-Novartis, research funding Ipsen, speaker Ipsen, AAA-Novartis. For the remaining authors, no conflicts of interest were declared.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.